Literature DB >> 20437113

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.

Sharis M Simonian1, Shahram Lotfipour, Christopher Wall, Mark I Langdorf.   

Abstract

The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF). The current recommendation for pharmacological treatment of this condition is amiodarone. A review of the past 25 years of literature finds several studies that identify a small risk of ventricular fibrillation secondary to amiodarone administration for rate control in WPW-AF. Additionally, the literature supports the safe and effective use of procainamide for rate control in WPW-AF. This review concludes that amiodarone is not superior to procainamide in rate control for WPW-AF, and may be dangerous.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20437113     DOI： 10.1007/s11739-010-0385-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


  13 in total

1.  The quest for a terminator.

Authors:  Richard O Cummins; Mary Fran Hazinski
Journal:  Ann Emerg Med       Date:  2006-01-25       Impact factor: 5.721

2.  [Electrophysiological properties of atrial fibrillation with WPW syndrome and the role of procainamide in conversion].

Authors:  P Li
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  1991-04

Review 3.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association.

Authors:  E N Prystowsky; D W Benson; V Fuster; R G Hart; G N Kay; R J Myerburg; G V Naccarelli; D G Wyse
Journal:  Circulation       Date:  1996-03-15       Impact factor: 29.690

4.  Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department.

Authors:  Marius A Tijunelis; Mel E Herbert
Journal:  CJEM       Date:  2005-07       Impact factor: 2.410

5.  Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation.

Authors:  W Schützenberger; F Leisch; K Kerschner; W Harringer; W Herbinger
Journal:  Br Heart J       Date:  1989-11

6.  Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation.

Authors:  L J Kappenberger; M A Fromer; W Steinbrunn; M Shenasa
Journal:  Am J Cardiol       Date:  1984-08-01       Impact factor: 2.778

7.  Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report.

Authors:  W Schützenberger; F Leisch; R Gmeiner
Journal:  Int J Cardiol       Date:  1987-07       Impact factor: 4.164

8.  Amiodarone is poorly effective for the acute termination of ventricular tachycardia.

Authors:  Keith A Marill; Ian S deSouza; Daniel K Nishijima; Thomas O Stair; Gary S Setnik; Jeremy N Ruskin
Journal:  Ann Emerg Med       Date:  2005-11-21       Impact factor: 5.721

9.  Wolff-Parkinson-White syndrome presenting in atrial fibrillation.

Authors:  I Schatz; G J Ordog; R Karody; V Bhasin
Journal:  Ann Emerg Med       Date:  1987-05       Impact factor: 5.721

10.  Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED.

Authors:  Brian T Fengler; William J Brady; Claire U Plautz
Journal:  Am J Emerg Med       Date:  2007-06       Impact factor: 2.469
View more
  8 in total

1.  [Rate and rhythm control in atrial fibrillation : pharmacological approaches].

Authors:  K F Weipert; D Erkapic; J Schmitt
Journal:  Herz       Date:  2015-02       Impact factor: 1.443

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 3.  Biochemistry and biology of mammalian DNA methyltransferases.

Authors:  A Hermann; H Gowher; A Jeltsch
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

4.  Acute rate control in atrial fibrillation: an urgent need for the clinician.

Authors:  Gheorghe-Andrei Dan; Anca R Dan; Andreea Ivanescu; Adrian C Buzea
Journal:  Eur Heart J Suppl       Date:  2022-06-13       Impact factor: 1.624

5.  Acute myocardial infarction in a patient with Wolff-Parkinson-White syndrome.

Authors:  Xu-Gang Tang; Jing Wen; Xue-Sen Zhang; Xiang-Jun Li; Da-Chun Jiang
Journal:  J Geriatr Cardiol       Date:  2018-09-28       Impact factor: 3.327

6.  Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.

Authors:  Jinzhu Hu; Jianhua Yu; Qi Chen; Jianxin Hu; Qianghui Huang; Zhen Xia; Zirong Xia; Zhenzhen Ju; Ping Yuan; Siyang Fan; Qinmei Xiong; Bo Zhu; Lin Huang; Chunjiao You; Huihui Bao; Yanqing Wu; Xiaoshu Cheng; Juxiang Li; Ali J Marian; Kui Hong
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

7.  Worsened Dysrhythmia after Chemical Cardioversion with Digoxin; a Case of Malpractice.

Authors:  Behrooz Hashemi; Mehdi Pishgahi; Marzieh Maleki
Journal:  Emerg (Tehran)       Date:  2014

8.  Tachyarrhythmia in Wolff-Parkinson-White Syndrome.

Authors:  Kelly Kesler; Shadi Lahham
Journal:  West J Emerg Med       Date:  2016-06-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.